Morning versus afternoon immunotherapy for advanced kidney cancer
Treatments studied
Part of Cancer, Kidney & urinary clinical trials.
This trial compares giving the same combination of two immunotherapy drugs in the morning versus the afternoon. It aims to see if timing affects how well the treatment works and how long people live.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be 18 or older.
- You must have advanced clear cell kidney cancer that is confirmed by biopsy.
- You must be scheduled to receive the standard immunotherapy combination of nivolumab and ipilimumab.
- You must be able to keep your infusion appointments at either before 11:30 a.m. or after 1:30 p.m. for the first four treatments.
- You must not work night shifts, have untreated moderate-to-severe sleep disorders, or have recently traveled across more than two time zones.
- You must not have other active cancers or untreated brain metastases.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests whether getting your immunotherapy infusion in the morning or in the afternoon makes any difference in how well it works. If you have certain types of advanced cancer and are about to start a standard FDA-approved immunotherapy, this study may help you and others by finding the best time of day for treatment.
This trial tests whether the time of day you receive immunotherapy (in the morning vs. later) affects how well it works. It is for people with advanced lung cancer or other solid tumors who are just starting or continuing PD-1/PD-L1 inhibitor treatment.
This trial studies the timing of a standard immunotherapy combination for advanced melanoma that cannot be removed by surgery or has spread. It aims to understand how timing affects treatment results.
This study compares two treatment plans for advanced kidney cancer: having surgery to remove the kidney tumor right away along with immunotherapy drugs (ipilimumab and nivolumab), versus starting the immunotherapy first and doing surgery later. The goal is to see if delaying surgery is just as good or better.
This trial tests whether giving immunotherapy at a specific time of day can improve its effectiveness for advanced melanoma that cannot be removed by surgery. It may help you if you have stage IV melanoma and have not had immunotherapy in the last year.
This study compares giving pembrolizumab (an immunotherapy drug) in the morning versus at a random time during the day, to see if timing affects how well it works or side effects. If you're eligible, you'll receive standard pembrolizumab treatment, but your infusion time will be assigned by the study.
Hear when a new Advanced Kidney Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.